EE03971B1 - (R)-(Z)-1-asabitsüklo[2.2.1]heptaan-3-oon-O-[3-(3-metoksüfenüül)-2-propünüül]oksiim maleaat kui farmatseutiline toimeaine - Google Patents

(R)-(Z)-1-asabitsüklo[2.2.1]heptaan-3-oon-O-[3-(3-metoksüfenüül)-2-propünüül]oksiim maleaat kui farmatseutiline toimeaine

Info

Publication number
EE03971B1
EE03971B1 EE9700316A EE9700316A EE03971B1 EE 03971 B1 EE03971 B1 EE 03971B1 EE 9700316 A EE9700316 A EE 9700316A EE 9700316 A EE9700316 A EE 9700316A EE 03971 B1 EE03971 B1 EE 03971B1
Authority
EE
Estonia
Prior art keywords
heptan
azabicyclo
propynyl
methoxyphenyl
active agent
Prior art date
Application number
EE9700316A
Other languages
English (en)
Estonian (et)
Other versions
EE9700316A (et
Inventor
Yoshihisa Ando Howard
Douglas Barrett Stephen
Carlos Jaen Juan
Edward Rose Steven
Tecle Haile
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE9700316A publication Critical patent/EE9700316A/xx
Publication of EE03971B1 publication Critical patent/EE03971B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
EE9700316A 1995-06-07 1996-05-13 (R)-(Z)-1-asabitsüklo[2.2.1]heptaan-3-oon-O-[3-(3-metoksüfenüül)-2-propünüül]oksiim maleaat kui farmatseutiline toimeaine EE03971B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/474,622 US5534522A (en) 1995-06-07 1995-06-07 (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
PCT/US1996/006814 WO1996040687A1 (en) 1995-06-07 1996-05-13 (r)-(z)-1-azabicyclo[2.2.1]heptan-3-one,o-[3-(3-methoxyphenyl)-2-propynyl]oxime maleate as a pharmaceutical agent

Publications (2)

Publication Number Publication Date
EE9700316A EE9700316A (et) 1998-06-15
EE03971B1 true EE03971B1 (et) 2003-02-17

Family

ID=23884337

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700316A EE03971B1 (et) 1995-06-07 1996-05-13 (R)-(Z)-1-asabitsüklo[2.2.1]heptaan-3-oon-O-[3-(3-metoksüfenüül)-2-propünüül]oksiim maleaat kui farmatseutiline toimeaine

Country Status (25)

Country Link
US (1) US5534522A (ko)
EP (1) EP0839148B1 (ko)
JP (1) JPH11506723A (ko)
KR (1) KR100383031B1 (ko)
CN (1) CN1063181C (ko)
AT (1) ATE187967T1 (ko)
BG (1) BG63571B1 (ko)
CA (1) CA2219753A1 (ko)
CZ (1) CZ286528B6 (ko)
DE (1) DE69605800T2 (ko)
DK (1) DK0839148T3 (ko)
EA (1) EA000381B1 (ko)
EE (1) EE03971B1 (ko)
ES (1) ES2142586T3 (ko)
GE (1) GEP19991874B (ko)
GR (1) GR3032772T3 (ko)
HK (1) HK1018055A1 (ko)
HU (1) HUP9802499A3 (ko)
NO (1) NO308901B1 (ko)
NZ (1) NZ307946A (ko)
PL (1) PL323796A1 (ko)
SK (1) SK282824B6 (ko)
UA (1) UA46032C2 (ko)
WO (1) WO1996040687A1 (ko)
ZA (1) ZA964764B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9601909A (pt) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
JP4933259B2 (ja) * 2003-10-02 2012-05-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ピロール置換インドリノン化合物の塩および多形
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
MX2007015511A (es) * 2005-06-07 2008-03-06 Univ Ramot Sales novedosas de farmacos sicotropicos conjugados y procesos para prepararlas.
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2051735B1 (en) 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010329440A1 (en) 2009-12-09 2012-08-09 Bar-Ilan University Methods of improving cognitive functions
AU2011219529A1 (en) 2010-02-24 2012-08-30 Bar-Ilan University Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
JP5997931B2 (ja) * 2011-05-25 2016-09-28 石原産業株式会社 農園芸用殺菌剤組成物及び植物病害の防除方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306718A (en) * 1990-03-06 1994-04-26 Warner-Lambert Company Oxime and amine substituted azabicyclo and azocyclo muscarinic agonists and methods of treatment
US5346911A (en) * 1990-03-06 1994-09-13 Warner-Lambert Company Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment

Also Published As

Publication number Publication date
EP0839148A1 (en) 1998-05-06
US5534522A (en) 1996-07-09
EA000381B1 (ru) 1999-06-24
DK0839148T3 (da) 2000-05-22
NO975704D0 (no) 1997-12-05
PL323796A1 (en) 1998-04-27
NO975704L (no) 1998-01-30
BG102078A (en) 1998-11-30
UA46032C2 (uk) 2002-05-15
AU5744996A (en) 1996-12-30
KR100383031B1 (ko) 2003-10-17
WO1996040687A1 (en) 1996-12-19
CZ286528B6 (cs) 2000-05-17
NZ307946A (en) 2001-03-30
EP0839148B1 (en) 1999-12-22
SK282824B6 (sk) 2002-12-03
BG63571B1 (bg) 2002-05-31
GR3032772T3 (en) 2000-06-30
HUP9802499A2 (hu) 1999-04-28
JPH11506723A (ja) 1999-06-15
AU697954B2 (en) 1998-10-22
CA2219753A1 (en) 1996-12-19
ZA964764B (en) 1997-01-08
ATE187967T1 (de) 2000-01-15
CN1063181C (zh) 2001-03-14
EA199800007A1 (ru) 1998-06-25
GEP19991874B (en) 1999-12-06
CN1186493A (zh) 1998-07-01
KR19990022572A (ko) 1999-03-25
SK164497A3 (en) 1998-06-03
ES2142586T3 (es) 2000-04-16
DE69605800D1 (de) 2000-01-27
HK1018055A1 (en) 1999-12-10
EE9700316A (et) 1998-06-15
CZ381797A3 (cs) 1998-05-13
HUP9802499A3 (en) 1999-06-28
DE69605800T2 (de) 2000-11-16
NO308901B1 (no) 2000-11-13

Similar Documents

Publication Publication Date Title
EE03971B1 (et) (R)-(Z)-1-asabitsüklo[2.2.1]heptaan-3-oon-O-[3-(3-metoksüfenüül)-2-propünüül]oksiim maleaat kui farmatseutiline toimeaine
TW332814B (en) Morphinan derivative
CA2149242A1 (en) Quinuclidine Derivative for Treatment of Inflammatory and Gastrointestinal Disorders
CA2358998A1 (en) Substituted bicyclic derivatives useful as anticancer agents
LU92132I2 (fr) Sel d'aclidinium avec anion d'un acide mono ou polyvalent pharmaceutiquement acceptable particulièrement le bromure d'aclidinium
GEP20032965B (en) Pharmaceutical Compound
CA2293823A1 (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
CA2107432A1 (en) Quaternary Basic Amides, Method of Preparing Them and Pharmaceutical Compositions in Which They Are Present
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
EE200000014A (et) (+)-nortsisapriidaluse valmistamismeetod, (+)-nortsisapriid, selle farmatseutiliselt vastuvõetav happe liitsool ja nende kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod ning vaheühend
CA2280328A1 (en) C11 carbamates of macrolide antibacterials
CA2300289A1 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
CA2220019A1 (en) Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
US5990125A (en) NK-1 receptor antagonists for the treatment of cancer
UA41353C2 (uk) Похідні алкілбензоїлгуанідинів, спосіб їх одержання, фармацевтична композиція, що має аритмічну активність
HU900255D0 (en) Process for preparation of 3-phenyl-5,6-dilhydrobenz (c)-acridine-carboxylic-acids and carboxylic-acid derivatives and for manufacturing of pharmaceutical composition containing these compounds as active ingredient
MX9708337A (es) Maleato (r)-(z)-1-azabiciclo [2.2.1]heptan-3-one,0-[3-(3-metoxifenil)-2-propinil]-oxime como un agente farmaceutico.
CA2227194A1 (en) Resolution of 1-azabicyclo[2.2.2]octan-3-amine, 2-(diphenylmethyl)-n-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]
CA2182812A1 (en) Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide
AU6919398A (en) Heterocyclic compounds and their preparation and use
CA2222552A1 (en) N-oxides as antibacterial agents
BG104162A (en) Pharmaceutical composition active in the reduction of the mcp-1 protein production
AU3978095A (en) Heterocyclic compounds and their preparation and use
SI0839148T1 (en) (r)-(z)-1-azabicyclo 2.2.1)heptan-3-one,o- 3-(3-methoxyphenyl)-2-propynyl)oxime maleate as a pharmaceutical agent

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20050513